Critical Survey: Nyxoah (NASDAQ:NYXH) vs. PolyPid (NASDAQ:PYPD)

Nyxoah (NASDAQ:NYXH) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Analyst Ratings

This is a breakdown of current ratings and price targets for Nyxoah and PolyPid, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	0	0	4	0	3.00
PolyPid	0	0	3	1	3.25

Nyxoah presently has a consensus target price of $16.25, indicating a potential upside of 62.34%. PolyPid has a consensus target price of $11.33, indicating a potential upside of 294.89%. Given PolyPid’s stronger consensus rating and higher possible upside, analysts clearly believe PolyPid is more favorable than Nyxoah.

Volatility & Risk

Nyxoah has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500.

Earnings & Valuation

This table compares Nyxoah and PolyPid”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$5.08 million	67.09	-$46.77 million	($1.87)	-5.35
PolyPid	N/A	N/A	-$29.02 million	($4.97)	-0.58

PolyPid has lower revenue, but higher earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nyxoah and PolyPid’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nyxoah	-1,043.93%	-51.68%	-40.11%
PolyPid	N/A	-624.10%	-129.28%

Insider & Institutional Ownership

26.5% of PolyPid shares are owned by institutional investors. 17.1% of Nyxoah shares are owned by company insiders. Comparatively, 24.7% of PolyPid shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

PolyPid beats Nyxoah on 8 of the 14 factors compared between the two stocks.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.